scispace - formally typeset
Open AccessBook ChapterDOI

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

TLDR
Based on a review of 51 cases of NBOMe toxicity reported in the literature, it appears that rhabdomyolysis is a relatively common complication of severe NBOME toxicity, an effect that may be linked toNBOMe-induced seizures, hyperthermia, and vasoconstriction.
Abstract
Serotonergic hallucinogens induce profound changes in perception and cognition. The characteristic effects of hallucinogens are mediated by 5-HT2A receptor activation. One class of hallucinogens are 2,5-dimethoxy-substituted phenethylamines, such as the so-called 2C-X compounds 2,5-dimethoxy-4-bromophenethylamine (2C-B) and 2,5-dimethoxy-4-iodophenethylamine (2C-I). Addition of an N-benzyl group to phenethylamine hallucinogens produces a marked increase in 5-HT2A-binding affinity and hallucinogenic potency. N-benzylphenethylamines (“NBOMes”) such as N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) show subnanomolar affinity for the 5-HT2A receptor and are reportedly highly potent in humans. Several NBOMEs have been available from online vendors since 2010, resulting in numerous cases of toxicity and multiple fatalities. This chapter reviews the structure–activity relationships, behavioral pharmacology, metabolism, and toxicity of members of the NBOMe hallucinogen class. Based on a review of 51 cases of NBOMe toxicity reported in the literature, it appears that rhabdomyolysis is a relatively common complication of severe NBOMe toxicity, an effect that may be linked to NBOMe-induced seizures, hyperthermia, and vasoconstriction.

read more

Citations
More filters
Journal ArticleDOI

Serotonin and brain function: a tale of two receptors

TL;DR: This bipartite model purports to explain how different drugs (SSRIs and psychedelics) that modulate the serotonergic system in different ways, can achieve complementary adaptive and potentially therapeutic outcomes.
Journal ArticleDOI

Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor

TL;DR: Comparisons of structures reveal determinants responsible for HTR2A-Gαq protein interactions as well as the conformational rearrangements involved in active-state transitions that could accelerate the discovery of more selective drugs for the treatment of a variety of neuropsychiatric disorders.
Journal ArticleDOI

Designer drugs: mechanism of action and adverse effects

TL;DR: Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects.
Journal ArticleDOI

Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions

TL;DR: Whether the inhibition of tryptophan hydroxylase (TPH) may provide an opportunity to pharmacologically target central 5-HT synthesis, and so develop new treatments for severe, life-threatening SS is discussed.
Journal ArticleDOI

Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?

TL;DR: The effect fingerprints highlight the main modes of action for the different NPS studied, including inhibition and/or reversal of monoamine reuptake transporters (cathinones and non‐hallucinogenic phenethylamines), activation of 5‐HT2receptors, activation of cannabinoid receptors (cannabinoids) and inhibition of NDMA receptors (arylcyclohexylamines).
References
More filters
Journal ArticleDOI

The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.

TL;DR: Decision rules (the Hunter Serotonin Toxicity Criteria) were developed that were simpler, more sensitive to serotonin toxicity and less likely to yield false positives.
Journal ArticleDOI

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

TL;DR: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.
Journal ArticleDOI

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

TL;DR: In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotics risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol.
Journal ArticleDOI

Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior

TL;DR: By genetically expressing 2AR only in cortex, it is shown that 2AR-regulated pathways on cortical neurons are sufficient to mediate the signaling pattern and behavioral response to hallucinogens.
Related Papers (5)